Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Dosage
181 Betamethasone Disodium Phosphate 0.1% Eye Ointment S01BA06162G5101XX A Non-infected inflammatory conditions of the eyes 2 - 4 times daily or at night when used with eye drops
182 Betamethasone Disodium Phosphate and Neomycin Sulphate 0.5% Ear Drops S03CA06991D1001XX B Allergic dermatosis in the ear Apply 2 - 3 drops 3 - 4 times daily, reduce frequency when relief obtained
183 Betamethasone Disodium Phosphate and Neomycin Sulphate Eye Drops S01CA05991D2001XX A Infected inflammatory conditions of the eyes 2 - 3 drops every 2 - 3 hours
184 Betamethasone Sodium Phosphate 4 mg/ml Injection H02AB01162P3001XX B Pre-operative and in serious trauma or illness, shock, as adjunctive therapy in rheumatoid disorders, ocular, dermatologic and respiratory allergic and inflammatory states Usual intravenous doses are up to 9 mg/day of the sodium phosphate salt only. CHILD: IM: 0.5 - 7.7 mg base/m2/day divided every 6 - 12 hours. ADOLESCENT and ADULT, IM: 0.6 - 9 mg divided every 12 - 24 hours
185 Bicalutamide 50 mg Tablet L02BB03000T1001XX A* Androgen deprivation therapy in advanced prostate cancer in combination with luteinising hormone-releasing hormone (LHRH) analogue therapy or surgical castration. 50 mg once daily. (morning or evening), with or without food. Take on the same time each day. Adult: When used with gonadorelin analogue: Usual dose: 50 mg once daily. May be started with or at least 3 days before starting gonadorelin analogue therapy.
186 Bimatoprost 0.01% ophthalmic solution S01EE03000D20-02XXX A* Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta blockers). One drop in the affected eye(s) once daily, administered in the evening.
187 Bisacodyl 10 mg Suppository A06AB02000S2002XX C i) Constipation ii) Bowel preparation for radiological procedures and surgery i) ADULT and CHILD over 10 years: 10 mg, CHILD less than 10 years 5 mg insert rectally ii) ADULT 10-20 mg, CHILD over 4 years 5 mg the following morning before procedures insert rectally
188 Bisacodyl 5 mg Suppository A06AB02000S2001XX C i) Constipation ii) Bowel preparation for radiological procedures and surgery i) ADULT and CHILD over 10 years: 10 mg, CHILD less than 10 years 5 mg insert rectally ii) ADULT 10-20 mg, CHILD over 4 years 5 mg the following morning before procedures insert rectally
189 Bisacodyl 5 mg Tablet A06AB02000T1001XX C i) Constipation ii) Bowel preparation for radiological procedures and surgery i) ADULT and CHILD over 10 years 5-10 mg, CHILD 4-10 years 5 mg. To be taken at night for effect on the following morning ii) ADULT 10-20 mg the night before procedures, CHILD over 4 years 5 mg the night before procedures
190 Bismuth Subnitrate, Iodoform and Liquid Paraffin Paste R01AX30984G6001XX B As a mild antiseptic for wounds and abscesses. Sterile gauze impregnated with paste for packing cavities after otorhinological surgery As directed for local application
191 Bisoprolol Fumarate 2.5 mg Tablet C07AB07000T1001XX B Treatment of stable moderate to severe congestive cardiac failure in addition to ACEI's and diuretics 1.25 mg once daily to 5 - 10 mg daily
192 Bisoprolol Fumarate 5 mg Tablet C07AB07000T1002XX B Treatment of stable moderate to severe congestive cardiac failure in addition to ACEI's and diuretics 1.25 mg once daily to 5 - 10 mg daily
193 Bleomycin 15 mg Injection L01DC01110P4001XX A Solid tumours; Lymphomas 15 - 30 mg weekly in divided doses or 10 - 20 mg/m2 once or twice weekly or 10 mg/m2 slow bolus in 15 minutes D1 and D15. Total dosage:should not exceed 300 mg. CHILD: 10 - 15 mg/m2 over 6 hours every 3 - 4 weeks (Routes: SC, IM, IV (either as bolus or as infusion over 24 hours), intra-arterial, intra-pleural)
194 Boric Acid with Spirit 2% w/v Ear Drops S02AA03000D1001XX C Perforated eardrum 3 drops instilled into affected ear 3 - 4 times daily
195 Bortezomib 3.5 mg Injection L01XX32000P3001XX A* i) Treatment of multiple myeloma in patient who have received at least one prior therapy. ii) For use in combination with conventional therapy for the treatment of previously untreated multiple myeloma patients who are not eligible for haematopoietic stem cell transplantation. 1.3 mg/ m2/dose given as IV bolus injection twice weekly for two weeks (days 1, 4, 8, and 11) followed by a 10- day rest period (days 12-21). At least 3 days should elapse between consecutive doses of bortezomib
196 Bosentan 125 mg tablet C02KX01000T1001XX A* For the treatment of pulmonary arterial hypertension (PAH) in patients with WHO Class III or IV symptoms, to improve exercise ability and decrease the rate of clinical worsening (To be used by those who are trained and specialized in treating and managing PAH) Initially 62.5 mg bd for 4 weeks, then increase to the maintenance dose of 125 mg bd
197 Brimonidine Tartrate 0.15% Ophthalmic S01EA05123D2001XX A* Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension 1 drop in the affected eye(s) 3 times daily
198 Brinzolamide 1% and Brimonidine tartrate 0.2% ophthalmic suspension S01EC54-990-D20-01-XXX A* Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction. 1 drop in the affected eye(s) 2 times daily.
199 Brinzolamide 1% ophthalmic suspension S01EC04-000-D20-01-XXX A* Approved Indication(s): Indicated for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. 1 drop 2 times daily. Some patients may have a better response with one drop three times a day. The dose should not exceed 1 drop in the affected eye(s) 3 times daily.
200 Bromazepam 3 mg Tablet N05BA08000T1002XX A Anxiety disorders Adult: Initially, 6-18 mg daily in divided doses. Doses up to 60 mg daily have been used. Elderly: Max initial dose: 3 mg daily
201 Bromhexine HCl 4 mg/2 ml Injection R05CB02110P3001XX A Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport 4mg SC, IM or IV 2 - 3 times daily (maximum 12mg/day).
202 Bromhexine HCl 4 mg/5 ml Elixir R05CB02110L1001XX B Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport Adult: 8-16 mg three times daily. Children: By body weight: 0.3 mg/kg/day 8 hourly for 7 days, then 0.15 mg/kg/day 8 hourly; or Based on age: 6-12 years – 4mg three times daily; 2-6 years – 2mg three times daily; Less than 2 years – 1mg three times daily.
203 Bromhexine HCl 8 mg Tablet R05CB02110T1001XX C Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport. Prescribing Restriction(s): Medical Assistant in health settings without Medical Officer is allowed to prescribe this medicine for adult use only. Adult: 8-16 mg three times daily. Children: By body weight: 0.3 mg/kg/day 8 hourly for 7 days, then 0.15 mg/kg/day 8 hourly; or Based on age: 6-12 years – 4 mg three times daily; 2-6 years – 2 mg three times daily
204 Bromocriptine Mesilate 10 mg Tablet G02CB01196T1003XX A/KK i) Hypogonadism or Galactorrhoea ii) Acromegaly i) Initially 1 - 1.25 mg at bedtime increased gradually, usual dose: 7.5 mg daily in divided doses. Max 30 mg daily ii) 1.25 - 2.5 mg at bedtime for 3 days and may be increased by 1.25 - 2.5 mg every 3 - 7 days up to 30 mg a day in divided doses
205 Bromocriptine Mesilate 2.5 mg Tablet G02CB01196T1001XX A/KK i) Hypogonadism or Galactorrhoea ii) Acromegaly i) Initially 1 - 1.25 mg at bedtime increased gradually, usual dose: 7.5 mg daily in divided doses. Max 30 mg daily ii) 1.25 - 2.5 mg at bedtime for 3 days and may be increased by 1.25 - 2.5 mg every 3 - 7 days up to 30 mg a day in divided doses
206 Bromocriptine Mesilate 5 mg Tablet G02CB01196T1002XX A/KK i) Hypogonadism or Galactorrhoea ii) Acromegaly i) Initially 1 - 1.25 mg at bedtime increased gradually, usual dose: 7.5 mg daily in divided doses. Max 30 mg daily ii) 1.25 - 2.5 mg at bedtime for 3 days and may be increased by 1.25 - 2.5 mg every 3 - 7 days up to 30 mg a day in divided doses
207 Budesonide 1 mg/2 ml Nebuliser Solution R03BA02000A3002XX B Maintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilators ADULT : Initially 1 - 2 mg twice daily. CHILD 3 months - 12 years of age : 500 mcg - 1 mg. Maintenance dose : half of the above doses
208 Budesonide 100 mcg/dose Inhaler R03BA02000A2101XX B Maintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilators ADULT:200 - 1600 mcg daily in 2-4 divided doses. Maintenance with twice daily dosing. CHILD more than 7 years: 200-800 mcg, 2 - 7 years: 200-400 mcg. To be inhaled in 2 - 4 divided doses.
209 Budesonide 160 mcg and Formoterol 4.5 mcg Inhalation R03AKO7989A2101XX A/KK i) Category of prescriber A/KK: Regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- - Patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists. or - Patients already adequately controlled on both inhaled corticosteroids and long- acting beta2-agonists. Category of prescriber A*: ii) Treatment of COPD patients with a blood eosinophil count of 300 cells/microliter and more iii) Treatment of COPD patients with blood eosinophil count of 100 cells/microliter and more with history of repeated exacerbation despite regular treatment with long-acting bronchodilators. Asthma Maintenance therapy Adult ≥18 yr 160 mcg to 320 mcg bd. Some patients may require up to a max of 640 mcg bd. Adolescent 12-17 yr 160 mcg to 320 mcg bd. Childn 6-11 yr 160 mcg bd, <6 yr Not recommended. Maintenance & relief Adult and adolescent ≥12 yr 320 mcg/day either as 160 mcg bd or 320 mcg od either morning or evening. For some patients a maintenance dose of 320 mcg bd may be appropriate. Patients should take 160 mcg additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 960 mcg should be taken on any single occasion. A total daily dose of more than 1280 mcg is not normally needed, however a total daily dose of up to 1920 mcg could be used for a limited period. Patients using more than 1280 mcg daily should seek medical advice, should be reassessed & their maintenance therapy reconsidered. Children & adolescent <12 yr: Not recommended. COPD: Adult ≥18 yr 320 mcg bd.
210 Budesonide 200 mcg/dose Inhalation R03BA02000A2102XX B Maintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilators ADULT: 200-1600 mcg daily in 2-4 divided doses. Maintenance with twice daily dosing. CHILD more than 7 years: 200-800 mcg, 2 - 7 years: 200-400 mcg. To be inhaled in 2-4 divided doses.

Halaman-halaman